|
|
Expression of Caspase-3 in Laryngeal Squamous Cell Carcinoma and its Relationship with Cell Apoptosis |
YU Yuan-chen1, ZHONG Zhao-kun2, LI Ji-xia1, YU Chuan-ting1 |
1. Department of Laboratory Medicine, Yantaishan Hospital, Yantai, Shandong, 264001, China;
2. Department of Medical Oncology, Yantaishan Hospital, Yantai, Shandong, 264001, China |
|
|
Abstract Objective: To investigate the expression ofCaspase-3 in laryngeal squamous cell carcinoma (LSCC) and its relationship with cell apoptosis. Methods: The expression of Caspase-3 protein in 43 LSCC tissues and 21 vocal cord polyp tissues was detected using immunohistochemical SP method; the apoptosis of LSCC was measured by in situ end-labeling (TUNEL) assay, and the relationships between Caspase-3 expression and clinicopathological features as well as cell apoptosis in LSCC tissue were analyzed. Results: The positive rate of Caspase-3 expression in LSCC tissue was lower than in vocal cord polyp tissue dramatically, with statistical significance (51.2% vs. 85.7%, P=0.007). Caspase-3 expression in LSCC tissue was closely related to the tumor differentiated degrees, clinical staging and presence or absence of lymph node metastasis (P=0.009, 0.001, 0.018) instead of the gender, age and tumor size (P>0.05). The apoptosis index (AI) of Caspase-3 was (4.31±0.49)% in LSCC tissue, while (24.28±1.07)% in vocal cord polyp tissue. Significant difference was presented between two groups by comparison to the AI (P<0.001). Spearman correlation analysis displayed that Caspase-3 expression in LSCC tissue had a significantly positive correlation with the number of positive TUNEL cells (r=0.435, P=0.000). Conclusion: Low expression of Caspase-3 protein might promote the tumorigenesis and progression by reducing the apoptosis of tumor cells, and detection to its protein can be considered as an important index for judging the differentiation, clinical staging, infiltration and metastasis of laryngeal carcinoma.
|
|
Corresponding Authors:
YU Chuan-ting, E-mail: sdytyct@163.com
|
|
|
|
2. Tian Y, Fu S, Qiu GB, et al (2014). MicroRNA-27a promotes proliferation and suppresses apoptosis by targeting PLK2 in laryngeal carcinoma. BMC Cancer, 2014, 14: 678.
3. Huang XE. Advances in translational medicine of breast cancer: from bench to bedside. J Int Transl Med, 2015, 3(1): 47-52.
4. Wang X , Pan J, Li J. Cytokine-induced apoptosis inhibitor 1 inhibits the growth and proliferation of multiple myeloma. Mol Med Rep, 2015, doi: 10.3892/mmr.2015.3656.
6. Xue Y, Wu L, Liu Y, et al. ENTPD5 induces apoptosis in lung cancer cells via regulating caspase 3 expression. PLoS One, 2015, 10 (3): e0120046.
9. Juraver-Geslin HA, Durand BC. Early development of the neural plate: new roles for apoptosis and for one of its main effectors caspase-3. Genesis, 2015, 53(2): 203-24.
11. Winter RN, Kramer A, Borkowski A, et al. Loss of caspase-1 and caspase-3 protein expression in human prostate cancer. Cancer Res, 2001, 61(3): 1227-32.
13. Wang TS, Ding QQ, Guo RH, et al. Expression of livin in gastric cancer and induction of apoptosis in SGC-7901 cells by shRNA mediated silencing of livin gene. Biomed Pharmacother, 2010, 64(5): 333-8.
14. Ashhab Y, Alian A, Polliack A, et al. Two splicing variants of a new inhibitor of apoptosis gene with different biological properties and tissue distribution pattern. FEBS Lett, 2001, 495(1-2): 56-60. |
[1] |
TAN Mi-duo. Research Progress of Translational Medicine in Breast Cancer[J]. Journal of International Translational Medicine, 2017, 5(2): 86-91. |
[2] |
Lukas Gietz, Benjamin Mayer. A Resampling Approach for Sample Size Estimation in Animal Experiments[J]. Journal of International Translational Medicine, 2017, 5(2): 53-62. |
[3] |
QIAN Ting, HUANG Xin-en. Comparison of the Efficacy and Safety of Pemetrexed-Based Versus Paclitaxel-Based Chemotherapy as Third-Line Treatment for Patients with Advanced Breast Cancer[J]. Journal of International Translational Medicine, 2017, 5(2): 63-66. |
[4] |
MAO Xiao-dong, ZHE Yi, CHEN Ya-jun, LIU Kang-sheng. Detection of Serum Anti-Müllerian Hormone Level for Women of Reproductive Age: A Cross-Sectional Study[J]. Journal of International Translational Medicine, 2017, 5(2): 67-70. |
[5] |
LIU Yong-jun, ZHOU Yan. Advances of PD-1/PD-L1 Inhibitors in Tumor Immunotherapy[J]. Journal of International Translational Medicine, 2017, 5(2): 80-85. |
[6] |
WANG Peng. Chimeric Antigen Receptor-Engineered T Cells in Tumor Immunotherapy: From Bench to Beside[J]. Journal of International Translational Medicine, 2017, 5(2): 92-97. |
|
|
|
|